Tirzepatide for Sleep Apnea: SURMOUNT-OSA Trial Shows Dramatic Results

The SURMOUNT-OSA program consisted of two parallel randomized, double-blind, placebo-controlled Phase 3 trials evaluating tirzepatide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Published in the New England Journal of Medicine, these trials represent the most rigorous evaluation of a GLP-1 class drug for sleep apnea to date.

Study 1 enrolled 234 participants with OSA who were not using CPAP therapy. Study 2 enrolled 235 participants who were already on CPAP but still had residual disease. All participants had a BMI of 30 or higher and moderate-to-severe OSA defined as an apnea-hypopnea index (AHI) of 15 or more events per hour.

Participants received tirzepatide (titrated to the maximum tolerated dose of 10 or 15 mg weekly) or placebo for 52 weeks. The primary endpoint was the change in AHI — the standard measure of sleep apnea severity that counts the number of times breathing stops or becomes dangerously shallow per hour of sleep.

The SURMOUNT-OSA results exceeded expectations, demonstrating substantial improvements in sleep apnea severity.

AHI reduction. Tirzepatide reduced AHI by approximately 25.3 events per hour in Study 1 (non-CPAP users) and 29.3 events per hour in Study 2 (CPAP users), compared to reductions of approximately 5 events per hour with placebo. This represents a relative reduction of approximately 55-63% from baseline.

Remission rates. Approximately 27% of tirzepatide-treated patients in Study 1 no longer met the diagnostic criteria for OSA (AHI <5 events/hour) at 52 weeks, compared to only 4% with placebo. More than 1 in 4 patients on tirzepatide were effectively cured of their sleep apnea.

Weight loss. Consistent with other tirzepatide trials, participants lost approximately 18-20% of body weight over 52 weeks.

Oxygen desaturation improvement. Beyond AHI, tirzepatide significantly improved the oxygen desaturation index, mean oxygen saturation during sleep, and time spent below 90% oxygen saturation — all critical measures of how severely sleep apnea disrupts breathing and oxygenation.

Patient-reported outcomes. Tirzepatide-treated patients reported significant improvements in daytime sleepiness (Epworth Sleepiness Scale), sleep quality, and functional status.

Obstructive sleep apnea affects an estimated 30-40 million Americans and is severely undertreated. Understanding the SURMOUNT-OSA significance requires knowing the current treatment landscape's limitations.

CPAP is effective but poorly tolerated. The standard treatment for moderate-to-severe OSA is continuous positive airway pressure (CPAP), which delivers pressurized air through a mask during sleep. CPAP is effective when used consistently, but 40-60% of patients do not use it regularly, citing discomfort, claustrophobia, noise, and inconvenience. Many patients abandon the device within a year.

Untreated OSA has serious consequences. Sleep apnea significantly increases the risk of hypertension, atrial fibrillation, stroke, heart failure, type 2 diabetes, motor vehicle accidents, and all-cause mortality. The cardiovascular burden makes untreated OSA a major public health concern.

A once-weekly injection changes the equation. For millions of patients who cannot tolerate CPAP, tirzepatide offers a fundamentally different treatment modality — a once-weekly injection that addresses the underlying obesity driving their airway obstruction, rather than mechanically propping the airway open each night. This is a shift from symptom management to disease modification.

The mechanism by which tirzepatide improves OSA is primarily through weight loss, but emerging evidence suggests additional pathways may contribute.

Weight loss reduces mechanical obstruction. Significant weight loss — 18-20% in SURMOUNT-OSA — reduces fat deposition around the pharynx, tongue base, and lateral pharyngeal walls. These fat deposits are the primary cause of airway narrowing and collapse during sleep in obesity-related OSA. Even 10% weight loss can reduce AHI by approximately 50%, and tirzepatide achieves nearly twice that.

Reduction of visceral and ectopic fat. Beyond subcutaneous fat, tirzepatide reduces visceral abdominal fat and ectopic fat deposits. Neck circumference — a strong predictor of OSA severity — decreases substantially with treatment.

Potential direct GLP-1 effects on respiratory control. Preclinical research has identified GLP-1 receptors in brainstem regions that control respiratory drive, including the nucleus tractus solitarius. This raises the possibility that GLP-1 agonism may directly enhance respiratory muscle tone, independent of weight loss. However, this remains speculative in humans.

Reduced systemic inflammation. OSA is associated with chronic low-grade inflammation, and tirzepatide has demonstrated anti-inflammatory effects (reductions in C-reactive protein). Reduced inflammation could improve upper airway neuromuscular function and decrease mucosal edema.

Tirzepatide is already FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). OSA would be a third indication via a supplemental New Drug Application (sNDA).

Expected timeline. Eli Lilly plans to submit an sNDA for tirzepatide in OSA based on the SURMOUNT-OSA data. Submission is anticipated in late 2026, with a potential FDA decision in 2027. The application may receive priority review given the unmet need.

Insurance implications. An FDA-approved OSA indication could significantly expand insurance coverage for tirzepatide, creating an additional coverage pathway for the 30+ million Americans with the condition.

Sleep medicine adoption. If approved, tirzepatide would be the first pharmacotherapy to receive an FDA indication for obstructive sleep apnea, establishing an entirely new treatment paradigm alongside CPAP and oral appliances.

Despite the impressive results, important limitations exist.

Obesity-related OSA specifically. SURMOUNT-OSA enrolled patients with BMI of 30 or higher. The results are most applicable to patients whose OSA is primarily driven by obesity. Patients with OSA caused by craniofacial anatomy or central sleep apnea are unlikely to see similar benefits.

Not a universal cure. While 27% achieved remission, the majority still had residual sleep apnea at 52 weeks. Some patients may still need CPAP or other therapies in combination with tirzepatide.

Weight regain upon discontinuation. Data from SURMOUNT-4 shows that weight regain occurs when treatment is stopped, implying that OSA benefits would also reverse. This makes tirzepatide a chronic therapy, not a cure.

Long-term outcomes unknown. Whether tirzepatide-induced AHI reductions translate to long-term reductions in cardiovascular events, stroke, or mortality has not been established. Longer outcome studies are needed.

Cost considerations. Zepbound costs approximately $1,000 per month without insurance. For patients using tirzepatide primarily for OSA, the cost-effectiveness compared to CPAP will be an important consideration for payers.